[Mechanisms of imiquimod indirect antiviral activity]
- PMID: 15771973
[Mechanisms of imiquimod indirect antiviral activity]
Abstract
The potential role of an immune response in HPV-related anogenital disorders had already been anticipated by clinicians. Indeed the lesions efflorescence and the relapsing HPV infection in HIV positive patients as well as the lack of recurrence in patients with spontaneous cure, provided relevant clues for a likely immune mechanism. At present time, the role of the immune system in the development of HPV-related anogenital disorders is well established : HPV induce a humoral and cell mediated immune response. This response is mainly exerted towards infected cells; it is also exerted at the systemic level, through antibodies synthesis, but this pathway remains a secondary one. Due to the limits of the present therapies (either purely destructive and characterized by the rate of recurrences, or antiviral, but difficult to use), it was necessary to find a new treatment type which enhances the local immune response, results in the disappearance of lesions and allows for a decrease in the risk of recurrences. The original mechanism of action of the first cell-mediated immune response modifier: imiquimod, for local use (Aldara 5 % cream) is an answer to this need. The first positive results observed in vitro and in animals were confirmed in patients with HPV anogenital warts in a double blind placebo-controlled study: imiquimod inhibits HPV replication and results in the condyloma regression. Its action is based on the combined activation of the natural local immunity, by stimulating interferon alpha; and of the acquired immunity, by stimulating a T-cell mediated immune response. Thus imiquimod appears to be an original antiviral compound, because it does not act directly on the virus itself.
Similar articles
-
Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.Arch Dermatol. 1998 Jan;134(1):25-30. doi: 10.1001/archderm.134.1.25. Arch Dermatol. 1998. PMID: 9449906 Clinical Trial.
-
Evaluation of imiquimod for the therapy of external genital and anal warts in comparison with destructive therapies.Br J Dermatol. 2007 Dec;157 Suppl 2:52-5. doi: 10.1111/j.1365-2133.2007.08274.x. Br J Dermatol. 2007. PMID: 18067633 Review.
-
Human papillomavirus (HPV) viral load and HPV type in the clinical outcome of HIV-positive patients treated with imiquimod for anogenital warts and anal intraepithelial neoplasia.J Eur Acad Dermatol Venereol. 2007 Sep;21(8):1054-60. doi: 10.1111/j.1468-3083.2007.02169.x. J Eur Acad Dermatol Venereol. 2007. PMID: 17714124 Clinical Trial.
-
Effect of imiquimod in anogenital warts from HIV-positive men.J Clin Virol. 2007 Jul;39(3):210-4. doi: 10.1016/j.jcv.2007.04.001. Epub 2007 May 21. J Clin Virol. 2007. PMID: 17513167 Clinical Trial.
-
Anogenital warts and other HPV-associated anogenital lesions in the HIV-positive patient: a systematic review and meta-analysis of the efficacy and safety of interventions assessed in controlled clinical trials.Sex Transm Infect. 2017 Dec;93(8):543-550. doi: 10.1136/sextrans-2016-053035. Epub 2017 Jun 21. Sex Transm Infect. 2017. PMID: 28637906 Review.
Cited by
-
Vegetative chronic genital herpes with satisfactory response to imiquimod.An Bras Dermatol. 2019 Mar-Apr;94(2):221-223. doi: 10.1590/abd1806-4841.20198014. Epub 2019 May 9. An Bras Dermatol. 2019. PMID: 31090830 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical